Subscribe To

Price Alert Latest News Economic Calendar News

RLMD / Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor (NMDAR) channel blocker and the Company's lead candidate. Read More

Demo Live Account See Partner Details

Content Topics

Relmada

Aces

Rel

1017

Ketamine

Study

Abuse

Potential

Rel 1017

Stock

RLMD

Posted: Feb 23 2022, 11:42

Author Name: Benzinga

RLMD News

By Seeking Alpha
October 13, 2023

Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024

Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying eff

By PRNewsWire
October 11, 2023

Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023

Low-dose psilocybin generated s tatistically significant reduc tions in liver fat content, plasma glucose levels and body weight gain in a mice model

By Zacks Investment Research
September 21, 2023

Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with ma

By Seeking Alpha
September 1, 2023

Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout

Relmada Therapeutics has provided updates on its phase 3 program of esmethadone (REL-1017) as an adjunct in major depressive disorder. An interim anal

By Seeking Alpha
May 12, 2023

Relmada Therapeutics, Inc. (RLMD) Q1 2023 Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisor

By PRNewsWire
May 8, 2023

Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023

CORAL GABLES, Fla. , May 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of

By Seeking Alpha
March 23, 2023

Relmada Therapeutics, Inc. (RLMD) Q4 2022 Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advis

By Market Watch
December 8, 2022

Relmada Therapeutics shares decline 40% on Thursday

Shares of Relmada Therapeutics Inc. RLMD, -0.95% tumbled about 40% in premarket trading on Thursday, the day after the company said its experimental d

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.